MDSpire - Takeaway
Clinical Guidelines

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

Share

  • 1

    Emerging treatment strategies discussed for advanced melanoma.

  • 2

    ImmTACs and TIL therapy are notable immune-based approaches.

  • 3

    Mucosal and uveal melanoma have different molecular drivers and prognoses.

  • 4

    The 15-gene expression profile categorizes risk for metastasis.

  • 5

    Kimmtrak (Tebentafusp) shows promise in treating metastatic uveal melanoma.

  • 6

    Lymphodepleting chemotherapy poses serious side effects.

  • 7

    Future directions include next-generation cell therapies.

Original Source(s)

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

  • by Alexandra Haugh, MD, Krista M. Rubin, MS, FNP-BC

  • March 30, 2026

Related Content

New Frontiers in Neuroendocrine Tumors: Enhancing Diagnosis, Treatment, and Patient Outcomes

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

These results come from the pilot phase of the phase III ADARNAT randomized international clinical trial, which is investigating whether axillary radiotherapy has a lower risk of lymphedema than axill...

Breast Cancer Recurrence Remains Low—Even After 10 Years—With Radiotherapy Tailored to Patient’s Individual Risk

“The results of our study show that tailoring the extent of radiotherapy according to how well the chemotherapy has worked to treat cancer in the lymph nodes leads to very low and reassuring recurrenc...